About MonTa Biosciences
MonTa Biosciences is a Healthcare company based in Copenhagen (Denmark) founded in 2013 by Thomas Lars Andresen. Liposomes are developed to deliver immunomodulators for cancer treatment. MonTa Biosciences has raised $3.97 million across 3 funding rounds from investors including PreSeed Ventures and Novo Holdings. The company has 4 employees. MonTa Biosciences was last valued at $12.24 million in January 2019. MonTa Biosciences offers products and services including MBS8. Its focus areas include Life Sciences, Immunotherapy, Diversified and Oncology. Its legal entity is MonTa Biosciences ApS.
Company details
MonTa Biosciences was founded in 2013 in Copenhagen, Denmark, and operates in the biotechnology sector. Liposome-based drug delivery technology is utilized to transport immune-stimulating compounds directly to immune cells in the blood for cancer treatment. The lead candidate consists of a liposome formulation of a TLR7 agonist, which stimulates the innate immune system. Development is planned in combination with radiation, chemotherapy, therapeutic antibodies, biologics, kinase inhibitors, and surgery.
- Headquarters Copenhagen, Denmark
- Employees 4
- Founders Thomas Lars Andresen
- Stage Minicorn
- SectorsHealthcare
- Website montabiosciences.com
- Social X
- Legal Name Monta Biosciences Aps
- Net Profit-$203.83 K (USD)-202as on Dec 31, 2022
- EBITDA-$458.7 K (USD)-24as on Dec 31, 2022
- Total Equity Funding$3.97M (USD)
in 3 rounds
- Latest Funding Round$3.49M (USD), Series A
Jan 2019
- InvestorsPreSeed Ventures
& 1 more
- Employee Count4
Products & Services of MonTa Biosciences
MonTa Biosciences offers a comprehensive portfolio of products and services, including MBS8.
LNP-based drug to enhance immune response against tumors
Funding Insights of MonTa Biosciences
MonTa Biosciences has successfully raised a total of $3.97M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3.49 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.97M
- Total Rounds 3
- Last Round Series A — $3.49M
- Investors Count 2
All 3 funding rounds of MonTa Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | $3.49M | Series A | $12.24M | – | – |
| Nov 2016 | $483,750 | Seed | $13.8M | PreSeed Ventures | – |
| Aug 2014 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Jan 2019 | $12.24M | •••••••• |
| Nov 2016 | $13.8M | •••••••• |
Last known valuation $12.24M (Jan 2019). 2 investors in total: 2 institutional.
Investors in MonTa Biosciences
MonTa Biosciences has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include PreSeed Ventures and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| preseedventures.dk |
Investor details for MonTa Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MonTa Biosciences
8 people are tracked at MonTa Biosciences (3 in leadership, 4 in board & advisors, 1 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Thomas Lars Andresen | Co-Founder | Leadership |
Simon Skjøde Jensen | CEO | Leadership |
Steven Glazer | CMO | Leadership |
Lone Schøtt Kunøe | Board Member | Board & advisors |
Sven Madsen | Board Member | Board & advisors |
Esper Boel | Board Member | Board & advisors |
Thomas L. Andresen | Co-Founder and Board Member | Board & advisors |
Morten Just Petersen | CDO | Team |
Complete people profiles for MonTa Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MonTa Biosciences
4 dated milestones of MonTa Biosciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded MonTa Biosciences is founded.
- Funding First funding round.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series A, of $3.5M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MonTa Biosciences
MonTa Biosciences was founded in 2013 and raised its 1st funding round 1 year after it was founded.
MonTa Biosciences is headquartered in Copenhagen, Denmark.
MonTa Biosciences is a funded company, having raised a total of $3.97M across 3 funding rounds to date.
MonTa Biosciences has 4 employees.
MonTa Biosciences was founded in 2013 in Copenhagen, Denmark, and operates in the biotechnology sector. Liposome-based drug delivery technology is utilized to transport immune-stimulating compounds directly to immune cells in the blood for cancer treatment. The lead candidate consists of a liposome formulation of a TLR7 agonist, which stimulates the innate immune system. Development is planned in combination with radiation, chemotherapy, therapeutic antibodies, biologics, kinase inhibitors, and surgery.
MonTa Biosciences offers MBS8.
MonTa Biosciences has 2 investors. Key investors include PreSeed Ventures, and Novo Holdings.
The valuation of MonTa Biosciences is $12.24M as of Jan 2019.
MonTa Biosciences operates through Monta Biosciences Aps.